RECRUITINGOBSERVATIONAL
Establishment of NAFLD Cohort and Development of Fibrosis Markers
Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis
About This Trial
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with diagnosed by tissue sample (biopsy-confirmed) fatty liver disease
- Patients with radiologically confirmed fatty liver disease
Who Should NOT Join This Trial:
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with histologically confirmed fatty liver disease
* Patients with radiologically confirmed fatty liver disease
Exclusion Criteria:
* History of significant alcohol consumption
* Viral hepatitis
* Autoimmune hepatitis
* Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
* Hepatotoxic medication (e.g. amiodarone)
Treatments Being Tested
PROCEDURE
Liver biopsy
Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
DEVICE
ARFI
Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
DEVICE
SWE
Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
DEVICE
Transient elastography
Transient elastography will be performed for evaluate fibrosis of liver.
Locations (1)
Seoul Metropolitan Government Seoul National University
Seoul, South Korea